.:: Iwan Darmansjah, MD. - Medical Articles ::.

.:: MEDICAL ARTICLES ::.

Medical Articles
Category: Safety Issues

Sitagliptin -a New Diabetes Drug- Reported Acute Pancreatitis

Sitagliptin (marketed as Januvia and Janumet) - acute pancreatitis
Audience: Diabetes healthcare professionals, patients

FDA notified healthcare professionals and patients of revisions to the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products. Eighty-eight post-marketing cases of acute pancreatitis, including two cases of hemorrhagic or necrotizing pancreatitis in patients using sitagliptin, were reported to the Agency between October 2006 and February 2009. It is recommended that healthcare professionals monitor patients carefully for the development of pancreatitis after initiation or dose increases of sitagliptin or sitagliptin/metformin. Sitagliptin has not been studied in patients with a history of pancreatitis. Therefore, it is not known whether these patients are at an increased risk for developing pancreatitis and the medication should be used with caution and with appropriate monitoring in patients with a history of pancreatitis. Considerations for healthcare professionals, information for patients, and a Data Summary are provided.

Read the complete MedWatch 2009 Safety summary including a link to the Information for Healthcare Professionals sheet, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm

--------------------------------------------------------------------------------

You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

Print Article

Send Article

Medical Articles Categories:
	Antibiotics
	Case Studies
	Clinical Trials
	Diabetes
	Drug Evaluation
	Education
	Ethical Issues
	General
	Herbal Medicine
	Rationaldruguse
	Safety Issues

Last 15 Medical Articles:
	Antibiotik Perlu Peroleh Klasifikasi Baru
	More Evidence Against Rosiglitazone
	Sistem Peresepan Obat Di Indonesia Bermasalah
	Difficult Safety Issues In Health
	Kebutuhan Pedoman Pengobatan
	Cerita Miring Dokter Indonesia Di Time
	Penicillin Injection For Community Acquired Pneumonia
	Peran Obat Dan Pengobatan Dalam Pengendalian Biaya Kesehatan
	How Wrong Diagnosis May End Up In High Cost
	More Safety Data On Exenatide, An Oral Antidiabetic
	American Roulette -- Contaminated Dietary Supplements
	Metformin Untuk Diabetes
	Hypoglycemia Linked With Mortality In Hospitalized Diabetic Patients Cme
	Probenecid Untuk Pirai
	Recall Of Propofol Injections (certain Lots)